Curcumin targets Akt cell survival signaling pathway in HTLV-I-infected T-cell lines

Cancer Science

Volumn 97, Issue 4, 2006, Pages 322-327

  Tomita, Mariko ^a   Matsuda, Takehiro ^a   Kawakami, Hirochika ^a   Uchihara, Jun Nosuke ^a   Okudaira, Taeko ^a   Masuda, Masato ^a   Ohshiro, Kazuiku ^b   Mori, Naoki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Naha Prefectural Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CURCUMIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; PROTEIN KINASE B; TURMERIC;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA CELL; LYMPHOID CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 33645358375     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00175.x     Document Type: Article

References (47)

1. Hinuma Y, Nagata K, Hanaoka M et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476-80.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-9.
3. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-5.
4. Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-10.
5. Osame M, Izumo S, Igata A et al. Blood transfusion and HTLV-I associated myelopathy. Lancet 1986; 2: 104 -5.
6. Yamada Y, Tomonaga M, Fukuda H et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 375-82.
7. Andjelkovic M, Alessi DR, Meier R et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997; 272: 31515-24.
8. Stephens L, Anderson K, Stokoe D et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998; 279: 710-4.
9. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000; 275: 8271-4.
10. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4: 257-62.
11. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1: 913-22.
12. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-97.
13. Liu Y, Wang Y, Yamakuchi M et al. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax. Oncogene 2001; 20: 2514-26.
14. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-8.
15. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
16. Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt: Implications for cancer therapy. Pharmacol Ther 2002; 93: 243-51.
17. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7.
18. Huang MT, Ma W, Yen P et al. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 1997; 18: 83-8.
19. Plummer SM, Holloway KA, Manson MM et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 1999; 18: 6013-20.
20. Lu YP, Chang RL, Huang MT, Conney AH. Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 1993; 14: 293-7.
21. Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl 1997; 27: 26-34.
22. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991; 88: 5292-6.
23. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995-5000.
24. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998; 17: 173-8.
25. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993; 14: 857-61.
26. Tomita M, Kawakami H, Uchihara JN et al. Curcumin (diferuloylmethane) inhibits constitutive active NF-κB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 2006; 118: 765-72.
27. Tomita M, Kawakami H, Uchihara JN et al. Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines. Leuk Res 2006; 30: 313-21.
28. Miyoshi I, Kubonishi I, Yoshimoto S et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294: 770-1.
29. Popovic M, Sarin PS, Robert-Gurroff M et al. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science 1983; 219: 856-9.
30. Koeffler HP, Chen IS, Golde DW. Characterization of a novel HTLV-infected cell line. Blood 1984; 64: 482-90.
31. Tomita M, Choe J, Tsukazaki T, Mori N. The Kaposi's sarcoma-associated herpes virus K-bZIP protein represses transforming growth factor β signaling through interaction with CREB-binding protein. Oncogene 2004; 23: 8272-81.
32. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996; 19: 1518-20.
33. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998; 273: 13150-6.
34. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-511.
35. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-14.
36. Alessi DR, Andjelkovic M, Caudwell B et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-51.
37. Balendran A, Casamayor A, Deak M et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999; 9: 393-404.
38. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 2005; 24: 6719-28.
39. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003; 89: 1-5.
40. Woo JH, Kim YH, Choi YJ et al. Molecular mechanisms of curcumin-induced cytotoxicity: Induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-208.
41. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, Slaga TJ. 4-Hydroxy-3-methoxybenzoic acid methyl ester: A curcumin derivative targets Akt/NFκB cell survival signaling pathway: Potential for prostate cancer management. Neoplasia 2003; 5: 255-66.
42. Sharma RA, Euden SA, Platton SL et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
43. Mori N, Fujii M, Ikeda S et al. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 1999; 93: 2360-8.
44. Mori N, Fujii M, Iwai K et al. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood 2000; 95: 3915-21.
45. Migone TS, Lin JX, Cereseto A et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269: 79-81.
46. Han SS, Keum YS, Seo HJ, Surh YJ. Curcumin suppresses activation of NF-κB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol 2002; 35: 337-42.
47. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-71.